BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Nov. 16, 2005
View Archived Issues
IDM Initiating Third Phase II Trial Of Uvidem In Melanoma
PARIS - IDM Pharma Inc. initiated another Phase II trial of its therapeutic vaccine Uvidem, which it is developing in collaboration with Sanofi-Aventis for the treatment of melanoma. (BioWorld International)
Read More
As Industry Changes, So Does Investing Criterion
Read More
New Oncogene Regulation Information Locates Target
Read More
Korea Touts Itself As Growth Region For Biotech Investing
Read More
SkyePharma Approached, Initiates Strategic Review
Read More
Other News To Note
Read More